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Our earlier research showed that racemic mix-
ture MG-1(R,S), 1-[2-hydroxy-3-(4-phenyl-1-piper-
azinyl)propyl]-pyrrolidin-2-one and its S-enan-
tiomer, significantly decreased systolic and diastolic
blood pressure, and possessed antiarrhythmic activ-
ity but the highest effect was shown by S-enan-
tiomer. R-enantiomer did not show antiarrhythmic
and hypotensive activity. S-enantiomer of MG-1
statistically diminished arrhythmias associated with
coronary artery occlusion and reperfusion in isolat-
ed rat hearts. This compound had affinity for α1 ñ
and α2 ñ adrenoceptors and antagonized the pressor
response elicited by epinephrine and methoxamine,
(1ñ4).
As a continuation of this study, 6 new analogs
of S-enantiomer of MG-1 with adrenolytic proper-
ties (active in adrenaline-induced arrhythmia) (4),
were tested in model ventricular arrhythmias associ-
ated with coronary artery occlusion and reperfusion
in the non-working isolated perfused rat heart and




The experiments were carried out on male
Wistar rats (180ñ250 g). Animals were housed in
constant temperature facilities exposed to 12:12 h
light-dark cycle and maintained on a standard pellet
diet and tap water given ad libitum. All procedures
were according to the Animal Care and Use
Committee Guidelines, and approved by the Ethical
Committee of Jagiellonian University, KrakÛw.
Control and experimental groups consisted of 6ñ8
animals each.
Drugs and compounds
All tested compounds (Scheme 1) were synthe-
sized in the Department of Physicochemical Drug
Analysis, Pharmaceutical Faculty, Jagiellonian
University. Synthesis of tested compounds was
described previously (4).
Barium chloride (POCh, Poland), sodium
heparin (Polfa), thiopental sodium (Biochemie
GmbH, Vienna), diphenylhydantoin sodium salt
(Epanutin, Parke-Davis), quinidine (Sigma Aldrich).
Ventricular arrhythmias associated with coronary
artery occlusion and reperfusion in the non-work-
ing isolated perfused rat heart 
Hearts from thiopental-anesthetized (45ñ60
mg/kg, ip) rats were perfused according to the
Langendorff technique (4ñ6), at constant pressure of
70 cm H2O (6.87 kPa) with Chenoweth-Koelle solu-
tion continuously gassed with 95% O2 plus 5% CO2
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Scheme 1. Structure of tested compounds and MG-1(S)
of the following composition (mmol/l): NaCl
(120.0), KCl (5.6), MgCl2 (2.2), NaHCO3 (19.0),
CaCl2 (2.4), and glucose (10.0).
The effect of tested compounds, in concentra-
tion of 10-8 to 10-4 M, on coronary flow (cardiac
effluent), electrocardiogram (obtained by two stain-
less steel electrodes, one inserted into the muscle of
the ventricular wall and another attached to the
metal aortic cannula) were assessed after 15ñ20 min
of initial stabilization.
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Non-working isolated hearts were mounted as
described above for recording coronary flow and
ECG. After a 15 min stabilization period, acute
regional myocardial ischemia was produced for 15
min by installing a clip on the left coronary artery
close to its origin (ischemic period). The clip was then
reopened, and changes during reperfusion were moni-
tored for 30 min (reperfusion period). Occlusion and
reperfusion were verified by measuring coronary flow
before occlusion, after occlusion and after reperfusion. 
Ligation of the coronary artery resulted in
24ñ28% reduction in coronary flow. Reperfusion
was followed by a return of the coronary flow.
Reperfusion induced arrhythmias manifested by
ventricular premature beats (VBs), ventricular
tachycardia (VT) and ventricular fibrillation (VF).
Electrocardiograms (ECGs) were analyzed
according to the guidelines of the Lambeth Conventions
for VBs, bigeminy, salvos (less than 4 successive VBs),
VT (4 or more successive VBs and VF.
In order to obtain a measure for the intensity of
the arrhythmias, an Arrhythmia Severity Index was
calculated for each heart according to Bernauer (7).
The following values were attributed: occurrence of
up to 10 ventricular extrasystoles during the first 30
min of reperfusion ñ 1, more than 10 ñ 2, VT or ven-
tricular flutter ñ 3, and VF ñ 4. Bigeminy and salvos
were not quantified separately but included with VBs.
Agents were added to the perfusion medium 15
min before coronary artery ligation and the concentra-
tion was maintained for the rest of the perfusion period.
Prophylactic antiarrhythmic activity in barium
chloride-induced arrhythmia (8)
Barium chloride solution was injected into the
caudal vein of rat (32 mg/kg, in a volume of 1
mL/kg). The tested compounds were given i.v. 15
min before arrhythmogen. The criterion of antiar-
rhytmic activity was a gradual disappearance of
arrhythmia and restoration of sinus rhythm.
Statistical analysis
The data are expressed as the means + SEM.
The data were evaluated by one-way analysis of
variance (ANOVA) followed by Duncan test; p <
0.05 was considered significant.
RESULTS 
Ventricular arrhythmias associated with coronary
artery occlusion and reperfusion in the non-work-
ing isolated perfused rat heart
During the 30 min period of coronary artery
reperfusion, all hearts in the control group devel-
oped VBs. The incidence of VT and VF was 60 and
50%, respectively (Table 1).
Compared with control hearts, all tested com-
pounds not significantly diminished the incidence of
VT and VF. The compounds reduced the incidence
of VT and VF at a concentration 10-5 M. At this con-
centration their arrhythmias severity index was sim-
ilar and had a value about 4.5 ñ 4.8 (control hearts
5.4) (Table 1). This effect was weaker comparative-
ly to MG-1(S). In previous studies compound MG-
1(S) significantly diminished the incidence of VT
and VF. In concentration 10-6ñ10-5 M it significantly
reduced the incidence of VBs (about 50ñ20%), VT
(about 90ñ80%) and VF (15%). The arrhythmias
severity index was lower (2.1 ñ 2.9), compared with
control hearts (Table 1). 
Reference drugs in this model; phenytoin and
quinidine (I class Vaughan Williams classification)
(8) showed significantly antiarrhythmic effect in this
test in concentrations 10-5 M (phenytoin) and 10-6ñ5
◊ 10-6 M (quinidine) (Table 1).
Influence of tested compounds on ECG parame-
ters on the non-working isolated perfused rat
heart
The six tested compounds (EP-79(S), EP-
81(S), EP-82(S), EP-86(S), EP-88(S) and EP-89(S))
decreased the number of cardiac beats per minute,
prolonged P-Q, Q-T, intervals and QRS complex.
All compounds in concentration 10-6 ñ 10-4 M
significantly decreased the number of cardiac beats
per minute (10-6 M: 9ñ14%; 10-4 M: 17ñ22%). This
chronotropic effect was similar to phenytoin (10-6 M:
11%; 10-4 M: 21%) and weaker than quinidine (10-7
M ñ 10-4 M: 17ñ35%) (Fig. 1).
The tested compounds in concentration 10-6 ñ
10-4 M significantly prolonged P-Q intervals (10-6 M:
14ñ25%; 10-4 M: 27ñ39%), Q-T intervals (10-6 M:
12ñ27%; 10-4 M: 24ñ39%) and QRS complex (10-6
M: 12ñ17%; 10-4 M: 23ñ31%), (Figs. 2ñ4). The elec-
trocardiographic changes observed after administra-
tion of the tested compounds were similar to those
observed for quinidine but weaker. Phenytoin simi-
larly prolonged P-Q and Q-T interval, but did not
change the QRS complex, (Figs. 1ñ4). The obtained
results suggest that the new pirrolidin-2-one deriva-
tives possess Ñquinidine-likeî properties. 
Prophylactic antiarrhythmic activity in barium
chloride-induced arrhythmia
For examined rats, intravenous injections of
high dose of barium chloride (32 mg/kg) caused a
rapid ventricular extrasystoles and VF in all animals
(100%), that led to death within 3ñ8 min. The tested
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compounds were given intravenously 15 min before
arrhythmogen. 
The highest activity was demonstrated by ref-
erence compound MG-1(S), which reduced inci-
dence of VF (by 20ñ60%) in doses 5, 10 and 20
mg/kg. At these doses it protected the animals
against death, too (by 10ñ60%). The ED50 value of
compound MG-1(S) was 10.4 mg/kg, (Table 2).
Compounds: EP-79(S), EP-81(S), EP-82(S),
EP-86(S), EP-88(S) and EP-89(S) possessed weak
antiarrhythmic properties, reduced incidence of ven-
tricular fibrillation in 10ñ33% in a dose of 10 mg/kg
and protected the animals against death by 10ñ20%
(Table 2).
DISCUSSION
In model ventricular arrhythmias associated
with coronary artery occlusion and reperfusion,
compound MG-1(R,S) and its S-enantiomer signifi-
cantly diminished the incidence of VT and VF. This
effect was similar to that of quinidine. It was sug-
gested that S-enantiomer had high affinity to α1-
adrenergic receptors and had the most antiarrhyth-
mic activity. On the ground of these results, new six
analogs of S-enantiomer MG-1 were investigated.
Binding studies presented in (4) showed that all
these compounds [(EP-79(S), EP-81(S), EP-82(S),
EP-86(S), EP-88(S) and EP-89(S)] displaced
Table 1. Effect of tested compounds on reperfusion-induced arrhythmias.
VBs Bigeminy Salvos VT VF Arrhytmias
Compound Concentration incidence incidence incidence incidence incidence severity index
(M) (%) (%) (%) (%) (%) 
Control - 100 50 30 60 50 5.4 ± 0.6  
10-6 100 60 20 50 30 4.9 ± 0.7
EP-79(S) 10-5 80 30 20 50 25 4.6 ± 1.2 
10-4 75 50 25 50 75 5.5 ± 0.6  
10-6 100 60 20 60 80 6.0 ± 0.4   
EP-81(S) 10-5 50 50 30 60 40 4.8 ± 1.2   
10-4 80 50 25 50 75 5.5 ± 0.3  
10-6 100 40 20 60 40 5.0 ± 0.5
EP-82(S) 10-5 100 50 20 60 20 4.5 ± 0.3
10-4 100 20 20 60 30 4.6 ± 0.4  
10-6 100 60 20 60 80 6.0 ± 0.6
EP-86(S) 10-5 50 100 40 60 40 4.8 ± 0.8
10-4 100 50 30 60 40 5.0 ± 0.3  
10-6 100 60 40 62.5 37.5 5.0 ± 0.2
EP-88(S) 10-5 100 25 25 62.5 25 4.5 ± 0.8
10-4 100 30 30 75 25 5.0 ± 0.5  
10-6 60 50 30 60 40 4.8 ± 0.6
EP-89(S) 10-5 100 40 30 50 40 4.8 ± 0.3
10-4 80 50 40 40 60 5.4 ± 1.1
10-6 50 25 0 10 10 2.1 ± 0.4 ***
MG-1(S) 10-5 80 20 0 20 10 2.9 ± 0.8*
10-4 100 50 17 33 33 4.0 ± 0.9
10-6 100 0 0 75 0 4.3 ± 0.3
PHENYTOIN 10-5 100 0 0 25 0 2.6 ± 0.4**
10-4 100 25 0 40 20 4.1 ± 0.7
QUINIDINE
10-6 83.3 16.7 0 50 0 2.3 ± 0.8 *
5 x 10-6 16.7 0 0 33.3 0 1.2 ± 0.6****  
Each value was obtained from 6ñ8 hearts. Significantly different vs. control: **** p < 0.001, *** p < 0.01, ** p < 0.02, * p < 0.05.
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Figure 1. Influence of tested compounds on heart rate
Figure 2. Influence of tested compounds on PñQ intervals
Figure 3. Influence of tested compounds on QRS complex
Figure 4. Influence of tested compounds on QñT intervals
Table 2. Prophylactic antiarrhytmic activity in barium chloride-induced arrhythmia.
Ventricular




EP-79(S) 15 - 20
EP-81(S) 33 - 10  




EP-88(S) 20 - 10  







15 60 40  
[3H]prazosin from cortical binding sites (Ki =
370ñ880 nM) and decreased pressor response elicit-
ed by epinephrine, norepinephrine and methoxam-
ine. These compounds injected intravenously 15
min before adrenaline, diminished the occurrence of
extrasystoles and reduced mortality (ED50 = 6.2 ñ
13.2 mg/kg) (4).
The antiarrhythmic activity of tested com-
pounds was examined in arrhythmia associated with
coronary artery occlusion and reperfusion rat mod-
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els. Many authors suggest that the rat coronary
artery ligation and reperfusion model can be recom-
mended as a screen for new antiarrhythmic agents
(9ñ13). It has been well known that α-blocking
agents (phentolamine, prazosin, corynanthine, rau-
wolscine and yohimbine) in relatively high doses
diminished or prevented reperfusion arrhytmias and
cardiac arrhythmias caused by adrenaline intoxica-
tion (7, 14ñ17). Phentolamine, a non-selective
blocker of α1- and α2-adrenoceptors, and the selec-
tive α1-adrenoceptor antagonist prazosin could
reduce the incidence of ischemia-induced ventricu-
lar fibrillation, which is in accordance with several
studies in the ischemic or reperfused rat, cat and dog
myocardium (18ñ25). All tested compounds had a
worse effect in this model of the arrhythmia com-
paratively to MG-1(S), which in a concentration of
10-5ñ10-6 M significantly diminished the incidence of
VT and VF. The arrhythmias severity index was
lower (2.1 ñ 2.9), compared with control hearts
(5.4). The antiarrhythmic activity of MG-1(S) in this
test was comparable to that reported for phenytoin
and quinidine.
The electrocardiographic changes observed
after administration of all tested compounds are sim-
ilar to those seen after administration of MG-1(S).
The changes in ECG were similar but significantly
weaker that those after quinidine (8). 
Only compound MG-1(S), contrary to tested
compounds, administered 15 min before barium
chloride in doses 10 and 15 mg/kg prevented in a
statistically significant manner the occurrence of VF
in 55ñ60%.
These results suggest that six new analogs of S
1-[2-hydroxy-3-(4-phenyl-1-piperazinyl)propyl]-
pyrrolidin-2-one have weaker antiarrhythmic effect
than the reference compound.
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